SynthesisCardiovascular and interventional radiology2026
Efficacy of Transarterial Radioembolization and Transarterial Chemoembolization as Downstaging or Bridging Strategies for Hepatocellular Carcinoma Before Liver Transplantation: A Systematic Review and Meta-Analysis.
Synthesis in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hepatocellular Carcinoma Bridging and Downstaging: Advances in Locoregional Therapy.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to compare transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) as locoregional therapies (LRT) for HCC patients awaiting liver transplantation (LT). MATERIALS AND
methodsWe conducted a systematic review with meta-analysis by searching PubMed, Embase, Web of Science, and Cochrane Library databases from inception until October 22, 2025. Twelve studies involving 10,661 patients were included. Studies comparing TARE and TACE for downstaging or bridging to LT in HCC patients were included. The primary outcome was downstaging rate. The protocol for this review was registered with PROSPERO under ID: CRD420251183741.
resultsThe analysis demonstrated no significant differences between TARE and TACE in key outcomes such as downstaging rate (OR 0.96; 95% CI 0.60-1.54; P = 0.88), transplantation rate (OR 0.89; 95% CI 0.66-1.21; P = 0.47), and recurrence rate (OR 1.26; 95% CI 0.69-2.28; P = 0.45). However, TARE was associated with fewer LRT sessions (MD -0.66; 95% CI -1.01 to -0.31; P = 0.0002), lower incidence of grade 3/4 bilirubin toxicities (OR 0.32; 95% CI 0.11-0.91; P = 0.03), and higher rates of complete tumor necrosis (OR 2.16; 95% CI 1.14-4.09; P = 0.02). Although no significant differences were observed in 1-year, 2-year, and 3-year overall survival (all p > 0.05), the pooled odds ratios consistently favored TARE (all OR > 1). Additionally, recurrence-free survival was significantly superior with TARE (OR 2.39; 95% CI 1.11-5.16; P = 0.03).
conclusionsWhile TARE and TACE demonstrate comparable efficacy in downstaging or bridging patients to LT, TARE may offer practical clinical advantages due to its enhanced oncologic efficacy, fewer treatment sessions, and a more favorable safety profile.
Indexed as
Identifiers
41706092What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.